News
Pfizer and Metsera signed an amendment to the merger agreement, and Metsera's board reiterated its support for the merger with Pfizer. Pfizer will acquire Metsera for $65.60 in cash per share plus up to $20.65 in contingent value rights
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments